Aficamten Succeeds in Phase III Non-Obstructive HCM Trial

Company: Cytokinetics · Drug: Aficamten (MYQORZO) · Trial: ACACIA-HCM (Phase III) · Indication: Non-Obstructive Hypertrophic Cardiomyopathy · Date: August 28, 2026 Summary Cytokinetics’ ACACIA-HCM trial met both co-primary endpoints for aficamten, marketed as MYQORZO for obstructive hypertrophic cardiomyopathy, in patients with non-obstructive hypertrophic cardiomyopathy, positioning…